news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
The Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.
More information on the event may be found here
